Citations

Clear

626 citation(s) found for "Mehta, SH".

Abstract P2-07-05: A clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced stage breast cancer treated with first-line endocrine therapy
Polley, M-YC, Dickler, M, Johnston, SR, Goetz, MP, Haba, J de la, Loibl, Sibylle , Rs, Mehta, Roberston, J, Barlow, William, Liu, Hai‐Xin, Tenner, Kathleen , Bergh, Joop P. van den , Roberston, J, Liu, H, Martin, M

Mayo Clinic

Cancer Research | May 11, 2019 | Volume: 79 | Issue: 4_Supplement | Pages: P2-07-05-P2-07-05

10.1158/1538-7445.sabcs18-p2-07-05 Get It

Abstract Purpose: Endocrine based therapy is an effective strategy to manage hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC). However, nearly all patients exhibit/develop either de novo or acquired resistance. While prognostic biomarkers of endocrine responsiveness are well established for the adjuvant treatment in ER+ breast cancer, less is known regarding prognostic and predictive biomarkers of response in the first line ABC setting. We sought to develop a clinical calculator based on clinical criteria for predicting progression-free survival (PFS) and overall survival (OS) of women with HR+/HER2- ABC who will be receiving endocrine monotherapy as first-line treatment for ABC. Methods: The development of the clinical calculator will be based on data from modern clinical trials in women with HR+/HER2- ABC. The studies to be included in the final analyses are given in Table 1. The control arm data from trials1-6 will form the training dataset (N = 1,223) and be used to construct the clinical prediction models. Variables considered include age, race, ECOG status, disease measurability, body mass index, disease-free interval, number of metastatic sites, locations of metastatic sites, prior endocrine therapy, and prior chemotherapy. Missing values will be imputed using single imputation with all variables included in the imputation model. For continuous variables, restricted cubic splines will be used to determine if non-linear effects may be more appropriate. The Lasso regression will be used as a variable selection technique to reduce the dimensionality of covariates; initially all pairwise interactions will be included in the model. Following Lasso regression, the multivariable Cox proportional hazards models will be constructed for PFS and OS including only variables retained in Lasso. The final model will be internally validated for discrimination and calibration using 10-fold cross-validation. External validation will be performed using control arm data from EGF 30008 (N = 536). Results: To date, control arm data from four trials (trials 1-4) have been received. The preliminary results presented here are based on pooled data from C40503 and LEA, for which data elements have been harmonized. Models for predicting PFS and OS have good calibration and are associated with bias-corrected C-indices of 0.61 and 0.65, respectively. These models will be updated using pooled data from trials 1-6. Conclusions: Our preliminary data demonstrate that clinical calculators based on baseline clinical factors can provide accurate prediction of PFS and OS in patients with HR+/HER2- ABC treated with first-line ET. If validated, these tools may be used for risk stratification in future clinical trials and to identify patients who may require more or less aggressive therapy. Table 1:Studies to be includedTrial NumberTrial NameTrial PISample Size in Control Arm1C40503Maura Dickler152 (letrozole)2LEAMiguel Martin179 (letrozole)3FACTJonas Bergh188 (anastrozole)4FALCONJohn Robertson194 (anastrozole)5S0226Rita Mehta345 (anastrozole)6MONARCH 3Matthew Goetz165 (nonsteroidal AI)7EGF 30008Stephen Johnston536 (letrozole) Citation Format: Polley M-YC, Dickler MN, Johnston S, Goetz MP, de la Haba J, Loibl S, Mehta RS, Bergh J, Roberston J, Barlow W, Liu H, Tenner K, Martin M. A clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced stage breast cancer treated with first-line endocrine therapy [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P2-07-05.
Abstract PD4-05: Molecular breast imaging and tomosynthesis to eliminate the reservoir of undetected cancer in dense breasts: The Density MATTERS trial
Rhodes, Deborah J. , Hunt, Katie N. , Conners, Amy Lynn , Zingula, Shannon N. , Whaley, Dana H. , Rl, Ellis, Spilde, Jeannette Gasal, Mehta, Ramila A. , Polley, M-Y, O’Connor, Michael K. , Ellis, R, Hruska, Carrie B.

Mayo Clinic

Cancer Research | May 11, 2019 | Volume: 79 | Issue: 4_Supplement | Pages: PD4-05-PD4-05

10.1158/1538-7445.sabcs18-pd4-05 Get It

Abstract Background High mammographic breast density is the primary reason for missed cancers or delayed detection on mammography, and is associated with a higher rate of advanced and interval cancers which increase breast cancer mortality. Digital breast tomosynthesis (DBT) has been shown to reduce false positive findings relative to 2D mammography but does not eliminate the potential for tumor masking in dense breasts due to the similar x-ray attenuation characteristics of tumors and normal fibroglandular tissue. Molecular Breast Imaging (MBI) performed with a dedicated gamma camera to detect functional uptake of a radiotracer, Tc-99m sestamibi, has been shown to reveal breast cancers obscured by density on mammography. In single-institution studies, adding MBI to 2D mammography in women with dense breasts detected an additional 5 to10 invasive cancers per 1000 screened, with modest increases in recall rate (6 to 8%) at a lower cost-per-cancer detected than mammography alone. Despite this promising evidence, the lack of multicenter trial data has limited wider acceptance. Also, MBI has yet to be compared to DBT, which in some centers has replaced 2D mammography screening. We present interim results from a multicenter trial comparing cancer detection rate of DBT and MBI in screening of women with mammographically dense breasts. Methods In this ongoing, prospective, multicenter clinical trial, asymptomatic women aged 40-75 years with dense breasts on prior mammogram and no prior history of supplemental screening are invited to undergo two annual rounds of concurrent DBT and MBI. MBI is performed with injection of 300 MBq Tc-99m sestamibi with a dual-head semiconductor-based gamma camera. Screening tests are interpreted independently. Here, preliminary cancer detection rates (cancers per 1000 women screened), recall rates, and biopsy rates of DBT and MBI for initial screening are reported. Results In 537 women out of a planned 3000 who have completed the first round of screening, 7 cancers were detected: one by DBT only and 6 by MBI only, giving cancer detection rates of 1.9 for DBT vs. 11.2 for MBI and incremental cancer detection rate of 9.3 for MBI. The one DBT-only cancer was a node-negative 0.8 cm invasive lobular carcinoma. All 6 cancers detected by MBI were invasive; 5 of 6 were node negative (median size 1.0 cm; range 0.6 to 2.6 cm). Recall rate was 11% (60/537) for DBT alone; 16% (84/537) for MBI alone, and 21% (115/537) for the combination. Biopsy was prompted by DBT in 13 patients (PPV 8% [1/13]); by MBI in 23 patients (PPV 26% [6/23]); and by the combination of modalities in 33 (PPV 21% [7/33]). Conclusion These preliminary results demonstrate that MBI detects invasive breast cancers occult on DBT in dense breasts. Data from a second screening round will allow calculation of sensitivity and specificity, and determination of the impact of screening MBI in reducing advanced (> 2 cm) and interval cancers. Additional planned analyses will evaluate a denoising algorithm for further reduction in MBI radiation dose to match that of DBT. Citation Format: Rhodes D, Hunt K, Conners A, Zingula S, Whaley D, Ellis R, Gasal Spilde J, Mehta R, Polley M-Y, O'Connor M, Hruska C. Molecular breast imaging and tomosynthesis to eliminate the reservoir of undetected cancer in dense breasts: The Density MATTERS trial [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr PD4-05.
Abstract P6-11-10: Preclinical efficacy of the novel PIM2 kinase inhibitor, JP11646 in triple negative breast cancer models
Mehta, Ranjit K. , Sangameswaran, D Kothai Guruswamy, Bezbatchenko, K, Gil, Małgorzata , Khoury, Thaer , Baldino, Camern, Caserta, Justin, Fetterly, Gerald J., Mehta, R, Moore, J, Lee, K, Adjei, A, Opyrchal, Mateusz

Mayo Clinic

Cancer Research | May 11, 2019 | Volume: 77 | Issue: 4_Supplement | Pages: P6-11-10-P6-11-10

10.1158/1538-7445.sabcs16-p6-11-10 Get It

Abstract Background: Triple negative breast cancer (TNBC) patients have poorer prognosis and there remains a lack of novel targeted therapies for their treatment. PIM2 (Proviral Integrations of Moloney virus 2) belongs to a family of three kinases that have been implicated in the survival and progression of hematologic malignancies and solid tumors. PIM2 has been linked to epithelial to mesenchymal transition in TNBC, which can lead to metastasis and chemotherapeutic resistance. We hypothesized that PIM2 may present as a therapeutic target in TNBC. Materials and Methods: The study involved both in vitro and in vivo studies involving a novel PIM2 inhibitor JP11646 (obtained from Jasco Pharmaceuticals). TNBC cell lines MDA-MB-231 and BT-549 were obtained for our in vitro studies. Cell viability was evaluated using MTT assay. Western Blot assay was used to evaluate relative protein expression. For in vivo studies, female SCID mice were inoculated in the mammary fat pads with 1 × 106 MDA-MB-231 cells. When tumor volumes reached 100 mm3, the mice were treated with JP11646 at the dosage 15mg/kg intraperitoneally for 2 consecutive days weekly for total of 4 weeks as determined from previous experiments. Control animals received vehicle only. The mice were euthanized once tumors reached ∼1,700 mm3. Results: BT-549 cells treated in vitro with 3 different available PIM kinase inhibitors AZD 1208, LGB321 and JP12641 showed only modest reduction in cell viability. However, treatment of both MDA-MB-231 and BT-549 with JP 11646 demonstrated significant reduction in cell viability with IC50 ranging from 40 to 71.6 nM. Treatment with JP11646 demonstrated a novel mechanism of action resulting in downregulation of PIM2 in both cell lines. Treatment with JP11646, but not other PIM kinase inhibitors, resulted in activation of apoptosis as measured by cleaved PARP (cPARP) levels. Anti-PIM2 siRNA treatment but not treatment with non-specific PIM kinase inhibitor AZD1208 resulted in cPARP induction. Inhibition of proteolysis by bortezomib resulted in preservation of PIM2 and inhibition of apoptosis as demonstrated by decreased cPARP levels after treatment with JP11646. PIM2 over-expressing clone of MDA-MB-231 cells showed enhanced proliferation and migration properties both in vitro and in vivo.Treatment of mice with orthotopically implanted MDA-MB-231 tumors with JP 11646 resulted in significant reduction in the tumor growth (p=0.0019) and increased overall survival (p=0.018) as compared to control mice. Conclusions: PIM2 upregulation in TNBC cell line resulted in more aggressive phenotype. JP11646, through novel mechanism of action resulting in degradation of PIM2, showed robust activity in TNBC cell lines both in vitro and in vivo. Further correlative studies in tumors harvested from in vivo experiments are ongoing. These results encourage further exploration of use of JP11646 as a targeted agent in treatment of TNBC. Citation Format: Mehta R, Kothai Guruswamy Sangameswaran D, Bezbatchenko K, Moore J, Gil M, Khoury T, Baldino C, Caserta J, Fetterly, Jr. G, Lee K, Adjei A, Opyrchal M. Preclinical efficacy of the novel PIM2 kinase inhibitor, JP11646 in triple negative breast cancer models [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P6-11-10.
Results of NRG oncology/RTOG 9813: A phase III randomized study of radiation therapy (RT) and temozolomide (TMZ) versus RT and nitrosourea (NU) therapy for anaplastic astrocytoma (AA).
Chang, Susan M. , Cairncross, J. Gregory , Bahary, Jean-Paul , Dolinskas, Carol A., Aldape, Kenneth , Schiff, David , Jaeckle, Kurt A. , Brown, Paul D. , Barger, Geoffrey, Werner‐Wasik, Maria, Brachman, David, Peñas-Prado, Marta , Robins, H. Ian, Bélanger, Karl, Schultz, Christopher J. , Zhang, Peixin, Gilbert, Mark R. , Chakravarti, Arnab , Shih, Helen A. , Mehta, Minesh P.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 2002-2002

10.1200/jco.2015.33.15_suppl.2002 Get It

Deep Brain Stimulation and Cognitive Outcomes Among Patients With Parkinson’s Disease: A Historical Cohort Study
Hansen, Allison , Kirlin, Kristin A., Limback-Stokin, Martin M. , Roesler, Kimberly, Velgos, Stefanie N., Lyons, Mark , Geda, Yonas E. , Mehta, Shyamal H. , Hansen, Allison L, Krell-Roesch, Janina, Lyons, Mark K, Geda, Yonas E , Krell‐Roesch, Janina

Mayo Clinic

The Journal of Neuropsychiatry and Clinical Neurosciences | February 22, 2019 | Volume: 31 | Issue: 3 | Pages: 196-200

10.1176/appi.neuropsych.18050118 | PMID 30791806 Get It

AIDS-Related Kaposi Sarcoma, Version 2.2019
Suneja, Gita , Ambinder, Richard F. , Ard, Kevin L. , Baiocchi, Robert A. , Cohen, Adam K. , Crysler, Oxana , Gupta, Neel K. , Gustafson, Chelsea, Hall, Andre, Johung, Kimberly L. , LaCasce, Ann S. , Lin, Chi , Menon, Manoj , Morgan, David , Nathwani, Nitya , Ratner, Lee , Rizza, Stacey A. , Sanchez, Julian , Taylor, Jeff , Tomlinson, Benjamin , Wang, Chia-Ching J., Dwyer, Mary A., CGC, Freedman-Cass, Deborah A., Rizza, Stacey , Ratner, Lee , Reid, Erin G , Barta, Stefan K , Carchman, Evie H. , Klopp, Ann H. , Mehta, Amitkumar , Noy, Ariela , Rudek, Michelle A. , Yendamuri, Sai S , CGC, Freedman-Cass, Deborah A., Ambinder, Richard F

Mayo Clinic

Journal of the National Comprehensive Cancer Network | February 20, 2019 | Volume: 17 | Issue: 2 | Pages: 171-189

10.6004/jnccn.2019.0008 | PMID 30787130 Get It

As treatment of HIV has improved, people living with HIV (PLWH) have experienced a decreased risk of AIDS and AIDS-defining cancers (non-Hodgkin’s lymphoma, Kaposi sarcoma, and cervical cancer), but the risk of Kaposi sarcoma in PLWH is still elevated about 500-fold compared with the general population in the United States. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for AIDS-Related Kaposi Sarcoma provide diagnosis, treatment, and surveillance recommendations for PLWH who develop limited cutaneous Kaposi sarcoma and for those with advanced cutaneous, oral, visceral, or nodal disease.
Impact of Balloon Guide Catheter Use on Clinical and Angiographic Outcomes in the STRATIS Stroke Thrombectomy Registry
Zaidat, Osama O. , Mueller‐Kronast, Nils , Hassan, Ameer E , Jadhav, Ashutosh P. , Froehler, Michael T. , Aziz‐Sultan, Mohammad Ali , Klucznik, Richard , Hellinger, Frank R, Yavagal, Dileep R. , Yao, Tom L., Gupta, Rishi , Martin, Coleman, Bozorgchami, Hormozd, Kaushal, Ritesh , Gandhi, Ravi H. , Peterson, Eric C. , Given, Curtis A., Mehta, Brijesh , Deshmukh, Vivek R., Starkman, Sidney , Linfante, Italo , McPherson, Scott H., Kvamme, Peter , Grobelny, Thomas, Hussain, Muhammad Shazam , Thacker, Ike, Vora, Nirav , Monteith, Stephen J., Ecker, Robert D., Schirmer, Clemens M. , Sauvageau, Eric , Chebl, Alex , Derdeyn, Colin P. , Maidan, Lucian, Badruddin, Aamir , Siddiqui, Adnan H. , Dumont, Travis M., Alhajeri, Abdulnasser, Taqi, Muhammad , Asi, Khaled, Carpenter, Jeffrey , Boulos, Alan S. , Jindal, Gaurav , Puri, Ajit S , Robinson, David , Kallmes, David F. , Baxter, Blaise, Jumaa, Mouhammad , Sunenshine, Peter, Majjhoo, Aniel, English, Joey , Fessler, Richard D., Delgado-Almandoz, Josser, Martin, Jerry C., Liebeskind, David S. , Investigators, on behalf of the STRATIS, Liebeskind, David S. , Siddiqui, Adnan H , Hassan, Ameer E , Schirmer, Clemens M , Jadhav, Ashutosh P , Haussen, Diogo C , Jahan, Reza , Saver, Jeffrey L. , Nogueira, Raul G. , Dashti, Shervin R , Chen, Peng R , Chitale, Rohan V , Deshaies, Eric Michael , Suzuki, Shuichi , Investigators, on behalf of the STRATIS, Derdeyn, Colin P

Mayo Clinic

Stroke | February 19, 2019 | Volume: 50 | Issue: 3 | Pages: 697-704

10.1161/strokeaha.118.021126 | PMID 30776994 Get It

Background and Purpose— Mechanical thrombectomy has been shown to improve clinical outcomes in patients with acute ischemic stroke. However, the impact of balloon guide catheter (BGC) use is not well established. Methods— STRATIS (Systematic Evaluation of Patients Treated With Neurothrombectomy Devices for Acute Ischemic Stroke) was a prospective, multicenter study of patients with large vessel occlusion treated with the Solitaire stent retriever as first-line therapy. In this study, an independent core laboratory, blinded to the clinical outcomes, reviewed all procedures and angiographic data to classify procedural technique, target clot location, recanalization after each pass, and determine the number of stent retriever passes. The primary clinical end point was functional independence (modified Rankin Scale, 0–2) at 3 months as determined on-site, and the angiographic end point was first-pass effect (FPE) success rate from a single device attempt (modified Thrombolysis in Cerebral Infarction, ≥2c) as determined by a core laboratory. Achieving modified FPE (modified Thrombolysis in Cerebral Infarction, ≥2b) was also assessed. Comparisons of clinical outcomes were made between groups and adjusted for baseline and procedural characteristics. All participating centers received institutional review board approval from their respective institutions. Results— Adjunctive technique groups included BGC (n=445), distal access catheter (n=238), and conventional guide catheter (n=62). The BGC group had a higher rate of FPE following first pass (212/443 [48%]) versus conventional guide catheter (16/62 [26%]; P =0.001) and distal access catheter (83/235 [35%]; P =0.002). Similarly, the BGC group had a higher rate of modified FPE (294/443 [66%]) versus conventional guide catheter (26/62 [42%]; P <0.001) and distal access catheter (129/234 [55%]; P =0.003). The BGC group achieved the highest rate of functional independence (253/415 [61%]) versus conventional guide catheter (23/55 [42%]; P =0.007) and distal access catheter (113/218 [52%]; P =0.027). Final revascularization and mortality rates did not differ across the groups. Conclusions— BGC use was an independent predictor of FPE, modified FPE, and functional independence, suggesting that its routine use may improve the rates of early revascularization success and good clinical outcomes. Clinical Trial Registration— URL: https://www.clinicaltrials.gov . Unique identifier: NCT02239640.
Workforce, Workload, and Burnout Among Intensivists and Advanced Practice Providers: A Narrative Review
Kvetan, Vladimír, Farmer, Joseph C. , Sessler, Curtis N., Christman, John W. , D’Agostino, Rhonda, Gregg, Sara, Khan, Roozehra, Kapu, April N. , Masur, Henry , Mehta, Gargi, Moore, Jason E. , Oropello, John M., Price, Kristen , Hite, R. Duncan , Farmer, J Christopher, Diaz-Gomez, Jose, Pastores, Stephen M. , Coopersmith, Craig M , Díaz‐Gómez, José L.

Mayo Clinic

Critical Care Medicine | January 26, 2019 | Volume: 47 | Issue: 4 | Pages: 550-557

10.1097/ccm.0000000000003637 | PMID 30688716 Get It

Objectives: To assess—by literature review and expert consensus—workforce, workload, and burnout considerations among intensivists and advanced practice providers. Design: Data were synthesized from monthly expert consensus and literature review. Setting: Workforce and Workload section workgroup of the Academic Leaders in Critical Care Medicine Task Force. Measurements and Main Results: Multidisciplinary care teams led by intensivists are an essential component of critical care delivery. Advanced practice providers (nurse practitioners and physician assistants) are progressively being integrated into ICU practice models. The ever-increasing number of patients with complex, life-threatening diseases, concentration of ICU beds in few centralized hospitals, expansion of specialty ICU services, and desire for 24/7 availability have contributed to growing intensivist staffing concerns. Such staffing challenges may negatively impact practitioner wellness, team perception of care quality, time available for teaching, and length of stay when the patient to intensivist ratio is greater than or equal to 15. Enhanced team communication and reduction of practice variation are important factors for improved patient outcomes. A diverse workforce adds value and enrichment to the overall work environment. Formal succession planning for ICU leaders is crucial to the success of critical care organizations. Implementation of a continuous 24/7 ICU coverage care model in high-acuity, high-volume centers should be based on patient-centered outcomes. High levels of burnout syndrome are common among intensivists. Prospective analyses of interventions to decrease burnout within the ICU setting are limited. However, organizational interventions are felt to be more effective than those directed at individuals. Conclusions: Critical care workforce and staffing models are myriad and based on several factors including local culture and resources, ICU organization, and strategies to reduce burden on the ICU provider workforce. Prospective studies to assess and avoid the burnout syndrome among intensivists and advanced practice providers are needed.
Teaching Video NeuroImages: MT-TL1 mutation presenting as chronic progressive external ophthalmoplegia
Parsons, Angela, Mehta, Shyamal H. , Acierno, Marie D, Dhamija, Radhika , Parsons, Angela M, Dhamija, Radhika

Mayo Clinic

Neurology | January 22, 2019 | Volume: 92 | Issue: 4 | Pages: No page available

10.1212/wnl.0000000000006817 | PMID 30665919 Get It